Market Place
Sourcing Support
Nordic Nanovector announces agreement to acquire Thor Medical
06 Jun 2023 //
PR NEWSWIRE
NORDIC NANOVECTOR - ANNUAL GENERAL MEETING POSTPONED
31 Mar 2023 //
PR NEWSWIRE
Invitation to Second Half and Full Year 2022 Results Presentation and Webcast
21 Feb 2023 //
PR NEWSWIRE
Nordic Nanovector faces board walkout after failed APIM merger
13 Dec 2022 //
FIERCEBIOTECH
Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 Jan 2023
13 Dec 2022 //
PRNEWSWIRE
Nordic Nanovector update shareholder vote against merger with APIM
09 Dec 2022 //
PRNEWSWIRE
Nordic Launches Area on Website in Norwegian for Proposed Merger with APIM
25 Nov 2022 //
BIOSPACE
Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
10 Nov 2022 //
PRNEWSWIRE
Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 1 Dec 2022
10 Nov 2022 //
PRNEWSWIRE
Nordic Nanovector gets second chance with APIM acquisition
10 Nov 2022 //
FIERCEBIOTECH
Nordic Shows Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies
03 Nov 2022 //
PRNEWSWIRE
Nordic Nanovector board members jump ship
16 Sep 2022 //
FIERCEBIOTECH
Nordic Nanovector consolidates Board to conserve resources
15 Sep 2022 //
PRNEWSWIRE
Nordic Nanovector consolidates senior leadership team and restructures
26 Aug 2022 //
PRNEWSWIRE
Troubled Nordic Nanovector “exploring strategic options”
19 Aug 2022 //
PHARMAPHORUM
Nordic Nanovector pulls the plug on troubled Paradigm trial
07 Jul 2022 //
FIERCEBIOTECH
Nordic Nanovector to Seek Regulatory Feedback on its Review and Data Evaluation
21 Jun 2022 //
PRNEWSWIRE
Nordic Nanovector to Conduct Review & Independent Data of PARADIGME PIIb Trial
01 Jun 2022 //
PRNEWSWIRE
Nordic Nanovector ASA: Allocation of RSUs to the board of directors
19 May 2022 //
PRNEWSWIRE
Nordic Nanovector ASA: Results for the First Quarter 2022
13 May 2022 //
PRNEWSWIRE
Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin
03 May 2022 //
PRNEWSWIRE
Nordic Nanovector ASA publishes Annual Report 2021
06 Apr 2022 //
PRNEWSWIRE
Nordic Nanovector ASA - Mandatory notification of trade - settlement of PSUs
23 Mar 2022 //
PRNEWSWIRE
Nordic Nanovector ASA: Extraordinary general meeting held
14 Feb 2022 //
PRNEWSWIRE
Nordic Nanovector Provides update on PARADIGME; Phase 2b Trial with Betalutin
07 Jan 2022 //
PRNEWSWIRE
Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021
25 Dec 2021 //
PRESS RELEASE
Nordic Nanovector appoints Pierre Dodion as Chief Medical Officer
08 Nov 2021 //
PRNEWSWIRE
Roche vet leaves Nordic Nanovector 3 months after joining as CEO
02 Jul 2021 //
FIERCEBIOTECH
Nordic Nanovector Announces Update from Archer-1 Ph1b Trial of Betalutin®
25 May 2021 //
PRNEWSWIRE
Nordic Nanovector Sees Significant Improvement in Patient Rate in PARADIGME
18 Feb 2021 //
PRNEWSWIRE
Nordic Nanovector publishes results of preclinical study demonstrating Betalutin
08 Oct 2020 //
PRES RELEASE
Independent Review Committee Recommends Nordic Nanovector to focus on one dosage
06 Aug 2020 //
PRNEWSWIRE
Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37
30 Jul 2020 //
PRNEWSWIRE
NETRIS Pharma Announces Clinical Trial Collab Agreement with MSD to NP137
05 May 2020 //
GLOBENEWSWIRE
Nordic Nanovector Announces Changes to its Executive Management Team
04 May 2020 //
PRNEWSWIRE
Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions
01 Apr 2020 //
PR NEWSWIRE
